Product logins

Find logins to all Clarivate products below.


Gout | Treatment Algorithms | Claims Data Analysis | US | 2024

Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) and characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the chronic management of hyperuricemia with urate-lowering therapies and is not considered in this study. The aim of chronic treatment is to prevent recurrent gout attacks and damage to the affected joints by lowering the concentration of sUA. Xanthine oxidase inhibitors (XOIs) are the mainstay of chronic gout treatment, with generic allopurinol prescribed extensively. Krystexxa is a highly efficacious biological drug reserved for later lines of therapy. This report provides important insights into how these agents are used in the management of chronic gout and how practices are evolving.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed gout? What are the quarterly trends in prescribing among recently treated and newly diagnosed gout patients?
  • How has Krystexxa been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of gout patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of gout patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

  • Markets covered: United States
  • Key companies: Horizon Pharma, Takeda Pharmaceuticals, Cardinal Health
  • Key drugs: Krystexxa, febuxostat, allopurinol, probenecid, probenecid / colchicine

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

KEY FEATURE

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…